Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.84% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ALNY · Sep 30, 2024
ALNYLAM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001178670-24-000053General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
8.73% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-33.26% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
15.17% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
83.63% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-15.35% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
54.09% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
9.14% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History31 statesSelf-history eligible
Jun 30, 20218/9 normalizedLevel 3Sep 30, 20218/9 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/9 normalizedLevel 3Jun 30, 20228/9 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 1.22%
- Current
- 0.84%
- Delta
- -0.38%
- Previous
- 18.82%
- Current
- 8.73%
- Delta
- -10.09%
- Previous
- 107.00%
- Current
- -33.26%
- Delta
- -140.26%
- Previous
- 12.73%
- Current
- 15.17%
- Delta
- 2.44%
- Previous
- 89.80%
- Current
- 83.63%
- Delta
- -6.17%
- Previous
- 7.37%
- Current
- -15.35%
- Delta
- -22.72%
- Previous
- 44.58%
- Current
- 54.09%
- Delta
- 9.51%
- Previous
- 13.53%
- Current
- 9.14%
- Delta
- -4.39%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ALNY Fundamental State →Has State · ALNYLAM PHARMACEUTICALS, INC. →Transitioned To · ALNY Fundamental State →Transitioned To · ALNY CAPEX_INTENSITY_DECREASED →Transitioned To · ALNY CASH_GENERATION_DECREASED →Transitioned To · ALNY GROWTH_DECREASED →Transitioned To · ALNY INVENTORY_PRESSURE_INCREASED →Transitioned To · ALNY MARGIN_DECREASED →Transitioned To · ALNY PROFITABILITY_DECREASED →Transitioned To · ALNY R_AND_D_INTENSITY_INCREASED →Transitioned To · ALNY SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.